| Market Cap | 3.77B | P/E | 42.01 | EPS this Y | - | Ern Qtrly Grth | -7.10% |
| Income | 88.91M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | - |
| Sales | 1.25B | PEG | - | EPS past 5Y | - | 200D Avg Chg | 20.00% |
| Dividend | 1.00% | Price/Book | 3.60 | EPS next 5Y | - | 52W High Chg | - |
| Recommedations | - | Quick Ratio | 1.80 | Shares Outstanding | 251.88M | 52W Low Chg | 74.00% |
| Insider Own | 0.34% | ROA | 4.91% | Shares Float | 250.86M | Beta | 0.65 |
| Inst Own | 59.32% | ROE | 8.98% | Shares Shorted/Prior | -/- | Price | 14.79 |
| Gross Margin | 32.56% | Profit Margin | 7.13% | Avg. Volume | 1,858 | Target Price | - |
| Oper. Margin | 11.12% | Earnings Date | - | Volume | 49,618 | Change | 0.00% |
UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services in the Republic of Ireland, the United Kingdom, North America, and internationally. The company operates in two segments, Ashfield and Sharp. The Ashfield segment offers commercialization services for the pharmaceutical and healthcare industry in the areas of advisory, communications, and commercial and clinical services. This segment supports healthcare professionals and patients at various stages of the product life cycle; and provides field and contact center sales teams, healthcare communications, patient support, audit, advisory, medical information, and event management services to approximately 300 healthcare companies. The Sharp segment provides contract and clinical trial packaging services for the pharmaceutical and biotechnology industries; serialization solutions; and clinical IRT services. The company was formerly known as United Drug plc and changed its name to UDG Healthcare plc in August 2013. UDG Healthcare plc was founded in 1948 and is headquartered in Dublin, the Republic of Ireland. As of August 16, 2021, UDG Healthcare plc was taken private.